Search Results - Abdel-Razeq H

  • Showing 1 - 15 results of 15
Refine Results
  1. 1

    Gonadotropin-releasing hormone agonists during chemotherapy for ovarian function and fertility preservation for patients with early-stage breast cancer by Abdel-Razeq H

    Published in Cancer Management and Research (2019-05-01)
    Get full text
    Article


  2. 2

    Advancing Germline Genetic Testing for Breast Cancer in Resource-Restricted Settings: Evidence, Barriers, and a Practical Roadmap for Implementation by Abdel-Razeq H

    Published in Breast Cancer: Targets and Therapy (2026-06-01)
    Get full text
    Article


  3. 3

    Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant Setting by Abdel-Razeq H, Sharaf B

    Published in Drug Design, Development and Therapy (2022-03-01)
    Get full text
    Article


  4. 4

    Dealing with thrombocytopenia during anticoagulation with heparins for active venous thromboembolism: a play-it-safe practical approach by Abdel-Razeq H, Ismael Y

    Published in Therapeutics and Clinical Risk Management (2011-06-01)
    Get full text
    Article


  5. 5

    Intravenous iron monotherapy for the treatment of non-iron-deficiency anemia in cancer patients undergoing chemotherapy: a pilot study by Abdel-Razeq H, Abbasi S, Saadi I, Jaber R, Abdulelah H

    Published in Drug Design, Development and Therapy (2013-08-01)
    Get full text
    Article


  6. 6

    Breast Cancer in Geriatric Patients: Current Landscape and Future Prospects by Abdel-Razeq H, Abu Rous F, Abuhijla F, Abdel-Razeq N, Edaily S

    Published in Clinical Interventions in Aging (2022-09-01)
    Get full text
    Article


  7. 7

    The application of clinical variables and models to predict pulmonary embolism in cancer patients: a comprehensive single cancer center experience by Mansour A, Ismael Y, Abunasser M, Hammode E, Turfa R, Abdel-Razeq H

    Published in Patient Preference and Adherence (2013-10-01)
    Get full text
    Article


  8. 8

    Patterns and Prevalence of BRCA1 and BRCA2 Germline Mutations Among Patients with Triple-Negative Breast Cancer: Regional Perspectives by Abdel-Razeq H, Tamimi F, Abujamous L, Edaily S, Abunasser M, Bater R, Salama O

    Published in Cancer Management and Research (2021-06-01)
    Get full text
    Article


  9. 9

    Escalation and De-Escalation Strategies for Endocrine Therapy in Early-Stage Breast Cancer by Al-Batsh T, Abdel-Razeq N, Al-Masri Y, El-Khatib O, Sharaf B, Tamimi F, Abdel-Razeq H

    Published in Biologics: Targets & Therapy (2025-03-01)
    Get full text
    Article


  10. 10

    Differences in Treatment Outcomes Between Patients with HER2-Low versus HER2-Zero, Hormone Receptor-Positive Advanced-Stage Breast Cancer Treated with Ribociclib by Sharaf B, Abu-Fares H, Tamimi F, Al-Sawajneh S, Salama O, Daoud R, Alhajahjeh A, Al-Lababidi S, Abdel-Razeq H

    Published in Breast Cancer: Targets and Therapy (2023-07-01)
    Get full text
    Article


  11. 11

    Clinicopathological Characteristics And Treatment Outcomes Of Breast Cancer Among Adolescents And Young Adults In A Developing Country by Abdel-Razeq H, Almasri H, Abdel Rahman F, Abdulelah H, Abu Nasser M, Salam M, Al-Dairi A, Natour O, Rimawi D

    Published in Cancer Management and Research (2019-11-01)
    Get full text
    Article


  12. 12

    Aggressiveness of Cancer Care at End of Life in Patients with Metastatic Breast Cancer in Jordan by Abunasser M, Abu-Fares H, Abdel-Razeq S, Shamieh O, Salama O, Ashouri K, Al Qudah A, Taqash A, Abu-Jaish H, Saadah SS, Abdel-Razeq H

    Published in Journal of Multidisciplinary Healthcare (2023-09-01)
    Get full text
    Article


  13. 13

    Clinical Outcomes of Patients Treated with Ribociclib in Combination with Aromatase Inhibitors or Fulvestrant for HR-Positive, HER2-Negative Metastatic Breast Cancer, Real-World Da... by Abdel-Razeq H, Sharaf B, Khater S, Baidoun HJ, Bani Hani H, Taqash A, El Khatib O, Edaily S, Abunasser M, Tamimi F, Al-Masri YN, Al-Batsh TMW, Zayed A, Ghatasheh T, Radaideh T

    Published in ImmunoTargets and Therapy (2024-09-01)
    Get full text
    Article


  14. 14

    Dual Anti-HER2 Therapy Vs Trastuzumab Alone with Neoadjuvant Anthracycline and Taxane in HER2-Positive Early-Stage Breast Cancer: Real-World Insights by Sharaf B, Tamimi F, Al-Abdallat H, Khater S, Salama O, Zayed A, El Khatib O, Qaddoumi A, Horani M, AL-Masri Y, Asha W, Altalla’ B, Bani Hani H, Abdel-Razeq H

    Published in Biologics: Targets & Therapy (2025-03-01)
    Get full text
    Article


  15. 15

    Bridging Clinical Trials to Real-World Clinical Practice: TCHP Neoadjuvant Therapy Outcomes in HER2-Positive Breast Cancer by Sharaf B, Seif A, Bani Hani H, Alhasan M, Khader R, Al-Yag'oub M, Ghanem A, Bani Ata J, Ajlouni B, Jawarneh Q, Jaffal A, Tamimi F, Jehad S, Al-Abdallat H, Mahafdah O, Abdel-razeq H

    Published in Breast Cancer: Targets and Therapy (2026-04-01)
    Get full text
    Article


Search Tools: